AstraZeneca and Regulus Therapeutics have partnered for the discovery, development and commercialisation of microRNA (miRNA) therapeutics for three exclusive targets that are in preclinical development. The collaboration includes Regulus’ lead cardiovascular/metabolic disease programme, which targets miR-33 for atherosclerosis. After a number of high-profile exits from the RNAi field, the deal may suggest a renewed willingness on the part of big pharma to embrace RNA technologies.